{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:45Z","timestamp":1790957745204,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The number of patients aged 80 years or older with diffuse large B-cell lymphoma (DLBCL) is increasing, and the incidence rate of the disease in this population group reaches up to 20%. The risk of infection is higher in older patients than in other patients. Although hypnotic drugs are frequently detected as potentially inappropriate medications, it is unclear whether hypnotic drugs affect the occurrence of infection during chemotherapy. Here, we investigated whether the use of hypnotic drugs is associated with infection during first-line chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) aged 80 years or older.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Japanese patients aged 80 years or older with diffuse large B-cell lymphoma who had received first-line chemotherapy at Fujita Health University Hospital from January 2005 to March 2020 were enrolled in this retrospective cohort study. The primary study outcome was the identification of the risk factor for infection during first-line chemotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>This study included 65 patients received first-line chemotherapy. The proportion of patients with National Comprehensive Cancer Network-international prognostic index \u2265 6 was higher in the infection group than in the non-infection group. The relative dose intensity of each anticancer drug (cyclophosphamide, adriamycin, and vincristine) and dose of prednisolone did not significantly differ between the two groups. Multivariate analysis showed that the use of benzodiazepines was a risk factor for infection (odds ratio, 4.131 [95% confidence interval: 1.225\u201313.94], <jats:italic>P<\/jats:italic> = 0.022).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>DLBCL patients using benzodiazepines should be monitored for infection symptoms during chemotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0269362","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T17:25:44Z","timestamp":1654881944000},"page":"e0269362","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study"],"prefix":"10.1371","volume":"17","author":[{"given":"Anna","family":"Ogiso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-392X","authenticated-orcid":true,"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"6","key":"pone.0269362.ref001","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"CR Flowers","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"pone.0269362.ref002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"SH Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"pone.0269362.ref003","doi-asserted-by":"crossref","first-page":"e0237509","DOI":"10.1371\/journal.pone.0237509","article-title":"Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma","volume":"15","author":"S Tsutsu\u00e9","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"pone.0269362.ref004","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1080\/10428194.2016.1236376","article-title":"Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan","volume":"58","author":"K Tajima","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"pone.0269362.ref005","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(11)70080-8","article-title":"Hope for very elderly patients with diffuse large B-cell lymphoma","volume":"12","author":"JM Ribera","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0269362.ref006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2011.09011.x","article-title":"Treatment of the elderly patient with diffuse large B cell lymphoma","volume":"157","author":"PA Fields","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0269362.ref007","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Z Zhou","year":"2014","journal-title":"Blood"},{"issue":"1","key":"pone.0269362.ref008","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1038\/s41598-017-04495-x","article-title":"Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma","volume":"7","author":"C Dendle","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0269362.ref009","article-title":"The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group","author":"K Asano","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"pone.0269362.ref010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12765","article-title":"Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study","volume":"165","author":"A Wieringa","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0269362.ref011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"MS Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"pone.0269362.ref012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis","volume":"9","author":"S Lanini","year":"2011","journal-title":"BMC Med"},{"issue":"4","key":"pone.0269362.ref013","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"pone.0269362.ref014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/CPP46072","article-title":"STOPP (Screening Tool of Older Person\u2019s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation","volume":"46","author":"P Gallagher","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"pone.0269362.ref015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bjh.17554","article-title":"Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma","volume":"194","author":"S Lee","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"pone.0269362.ref016","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00432-020-03279-7","article-title":"Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"146","author":"M Yamamoto","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"pone.0269362.ref017","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cam4.2008","article-title":"The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients","volume":"8","author":"M D\u0142ugosz-Danecka","year":"2019","journal-title":"Cancer Med"},{"issue":"17","key":"pone.0269362.ref018","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","article-title":"Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era","volume":"123","author":"N Howlader","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"pone.0269362.ref019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2012.06.004","article-title":"Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens","volume":"12","author":"P Lugtenburg","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"pone.0269362.ref020","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","article-title":"Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)","volume":"58","author":"VA Morrison","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"pone.0269362.ref021","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12185-020-02984-w","article-title":"Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data","volume":"112","author":"S Matsuda","year":"2020","journal-title":"Int J Hematol"},{"issue":"4","key":"pone.0269362.ref022","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/10428194.2017.1365856","article-title":"The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL\u2014comparative study","volume":"59","author":"L Vidal","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"pone.0269362.ref023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0609.2007.00877.x","article-title":"Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma","volume":"79","author":"D Tholstrup","year":"2007","journal-title":"Eur J Haematol"},{"issue":"3","key":"pone.0269362.ref024","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1634\/theoncologist.2019-0085","article-title":"Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy","volume":"25","author":"S Hong","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"pone.0269362.ref025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.16743","article-title":"Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma","volume":"192","author":"S Lee","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0269362.ref026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-018-2446-0","article-title":"Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria","volume":"74","author":"FR Motter","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pone.0269362.ref027","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12877-017-0674-2","article-title":"Potentially inappropriate prescriptions for elderly people taking antidepressant: comparative tools","volume":"17","author":"I Fulone","year":"2017","journal-title":"BMC Geriatr"},{"key":"pone.0269362.ref028","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbi.2015.08.011","article-title":"GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations","volume":"51","author":"K Ramirez","year":"2016","journal-title":"Brain Behav Immun"},{"issue":"1\u20133","key":"pone.0269362.ref029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-5728(91)90157-3","article-title":"Benzodiazepine anesthesia in humans modulates the interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 responses of blood monocytes","volume":"35","author":"V Taupin","year":"1991","journal-title":"J Neuroimmunol"},{"issue":"1","key":"pone.0269362.ref030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00000542-200607000-00019","article-title":"Midazolam inhibits proinflammatory mediators in the lipopolysaccharide-activated macrophage","volume":"105","author":"SN Kim","year":"2006","journal-title":"Anesthesiology"},{"issue":"1","key":"pone.0269362.ref031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-11-13","article-title":"The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions","volume":"11","author":"OS Yousefi","year":"2013","journal-title":"Cell Commun Signal"},{"key":"pone.0269362.ref032","doi-asserted-by":"crossref","first-page":"682612","DOI":"10.3389\/fimmu.2021.682612","article-title":"Diazepam Impairs Innate and Adaptive Immune Responses and Ameliorates Experimental Autoimmune Encephalomyelitis","volume":"12","author":"CR Falc\u00f3n","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0269362.ref033","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5664\/jcsm.27552","article-title":"Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem","volume":"5","author":"FL Joya","year":"2009","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"pone.0269362.ref034","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/000348940611500503","article-title":"Human adult deglutition during sleep","volume":"115","author":"K Sato","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"pone.0269362.ref035","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1378\/chest.127.5.1658","article-title":"Predictors of heartburn during sleep in a large prospective cohort study","volume":"127","author":"R Fass","year":"2005","journal-title":"Chest"},{"issue":"1","key":"pone.0269362.ref036","doi-asserted-by":"crossref","first-page":"13760","DOI":"10.1038\/s41598-019-50295-w","article-title":"Combined Effects of Having Sleep Problems and Taking Sleeping Pills on the Skeletal Muscle Mass and Performance of Community-Dwelling Elders","volume":"9","author":"CW Yang","year":"2019","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T17:26:15Z","timestamp":1654881975000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269362"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269362","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}